Table 2. ATN-161-associateda adverse events by dose level.
| MedDRA preferred term | Number of patients |
|---|---|
| 0.5 mg kg −1 | 1 |
| Muscle cramps | 1 |
| Sweating increased | 1 |
| 1.0 mg kg −1 | 1 |
| Dry mouth | 1 |
| Cellulitis | 1 |
| Pain in limb | 1 |
| Paresthesia | 1 |
| Phlebitis not otherwise specified (NOS) | 1 |
| 2.0 mg kg −1 | 2 |
| Oral candidiasis | 1 |
| Anemia NOS | 1 |
| Hypotension NOS | 1 |
| 4.0 mg kg −1 | 2 |
| Nausea | 2 |
| Constipation | 1 |
| Fatigue | 1 |
| 8.0 mg kg −1 | 1 |
| Nausea | 1 |
| 16.0 mg kg −1 | 1 |
| Hypotension NOS | 1 |
a
Possible, probable or definite relationship to study medication according to the investigator.